Safety Management of Severe Alcohol Use Disorder

Definition & Screening

• Severe alcohol use disorder is diagnosed when a patient meets six or more of the eleven DSM‑5 criteria (e.g., tolerance, withdrawal, craving, failed attempts to cut down, continued use despite harm, impaired functioning)【1】【2】.
• The AUDIT questionnaire is recommended for systematic screening; a score of 8 or higher identifies hazardous drinking that warrants intervention【1】【2】.

Immediate Risk Assessment & Indications for Hospitalization

• Patients who consume >80 g of alcohol per day for ≥10 years, or who have a history of withdrawal seizures or delirium tremens, should be managed as in‑patient because of high risk for life‑threatening withdrawal【3】【4】.
• Evaluation must include assessment for alcohol‑related medical complications such as alcoholic liver disease, gastrointestinal bleeding, pancreatitis, infection, electrolyte disturbances (especially magnesium), and hepatic encephalopathy【3】【4】.
• Hospital admission is indicated for any of the following:

Pharmacologic Management of Alcohol Withdrawal

• Benzodiazepines are the only proven therapy to prevent seizures and reduce mortality from delirium tremens in alcohol withdrawal【3】【5】.
• Long‑acting benzodiazepines (e.g., diazepam 5‑10 mg PO/IV every 6‑8 h or chlordiazepoxide 25‑100 mg PO every 4‑6 h) provide superior seizure protection for most patients【3】【4】.
• Short‑acting benzodiazepines (e.g., lorazepam 1‑4 mg PO/IV/IM every 4‑8 h) are preferred in the elderly, in patients with hepatic dysfunction, respiratory compromise, or recent head trauma【3】【5】【4】.

Mandatory Thiamine Administration

• Thiamine must be administered before any glucose‑containing IV fluids to all patients with severe AUD to prevent acute Wernicke encephalopathy【3】【4】.
• Prophylactic dosing: 100‑300 mg per day PO or IV for 4‑12 weeks【3】【4】.
• Therapeutic dosing for established Wernicke encephalopathy: 100‑500 mg per day IV for 12‑24 weeks【3】【4】.

Supportive Care & Monitoring

• Provide fluid and electrolyte replacement, with particular attention to correcting magnesium depletion【3】.
• Frequent vital‑sign monitoring is required to detect autonomic instability (tachycardia, hypertension, hyperthermia, sweating)【3】【4】.

Management of Specific Complications

• Seizures during withdrawal are best treated with benzodiazepines; anticonvulsants such as phenytoin or carbamazepine are not recommended because they are ineffective and may worsen outcomes【4】.
• Delirium tremens typically emerges 48‑72 h after cessation and presents with confusion, hallucinations, and severe autonomic instability【3】【4】. Aggressive escalation of benzodiazepine dosing is advised, and haloperidol 0.5‑5 mg PO/IM may be added as adjunctive therapy for severe agitation or psychosis, but never as monotherapy【3】【4】.

Long‑Term Relapse Prevention

• Mandatory psychiatric consultation is required for every patient with severe AUD to guide acute management and develop a long‑term abstinence plan【3】【4】.
• Pharmacologic relapse‑prevention options:

Ongoing Monitoring & Follow‑Up

• After withdrawal stabilization, continue thiamine supplementation for 2‑3 months to support neurologic recovery【3】【4】.
• Ongoing evaluation should include surveillance for dehydration, electrolyte imbalance, infection (e.g., pneumonia, spontaneous bacterial peritonitis), gastrointestinal bleeding, pancreatitis, and hepatic encephalopathy【3】【4】.

Management of Alcoholic Withdrawal in Hospital Settings

Initial Assessment and Triage

• The American College of Physicians recommends admitting patients with severe withdrawal symptoms, such as delirium, seizures, or delirium tremens, for close monitoring and treatment 6, 7
• Patients with concurrent serious physical or psychiatric disorders, inadequate social support, or a history of complicated withdrawal should also be admitted for hospital care 6
• Malnourished patients or those with suspected Wernicke's encephalopathy require prompt thiamine administration and close monitoring 6

Pharmacological Management Algorithm

• The American Society of Addiction Medicine recommends using benzodiazepines as the first-line treatment for alcohol withdrawal, with long-acting agents like diazepam preferred for most patients 6, 7, 8
• For patients with hepatic dysfunction, advanced age, or respiratory compromise, lorazepam is recommended due to its safer pharmacokinetics 7, 9
• The treatment should be limited to 10-14 days to prevent iatrogenic dependence, and benzodiazepines should be dispensed in small quantities or supervised to reduce misuse risk 6, 8, 10

Management of Seizures

• Benzodiazepines are effective in preventing and treating alcohol withdrawal seizures through GABA activation, and should be used as the primary treatment 6, 9
• Anticonvulsants, such as phenytoin or carbamazepine, should not be used to prevent further withdrawal seizures, as they are ineffective for this indication and may worsen outcomes 6, 7, 9

Management of Severe Withdrawal Delirium

• For delirium tremens refractory to adequate benzodiazepine doses, antipsychotics like haloperidol may be added as adjuncts to benzodiazepines, but should never be used as monotherapy 6, 10
• Antipsychotics alone can lower the seizure threshold and worsen outcomes, and should be used with caution 10

Essential Adjunctive Treatments

• Thiamine administration is mandatory for all patients with alcohol withdrawal, with a standard dose of 100-300 mg/day orally, and parenteral thiamine for high-risk patients 6, 7, 8
• Thiamine should be administered before any dextrose-containing solutions to prevent precipitating Wernicke's encephalopathy 10

Monitoring and Supportive Care

• Frequent vital sign monitoring is essential for detecting autonomic instability, such as tachycardia, hypertension, hyperthermia, and sweating 7
• Common comorbidities, such as dehydration, electrolyte imbalances, gastrointestinal bleeding, pancreatitis, infection, and head trauma, should be evaluated and managed promptly 7
• Psychiatric consultation is recommended for evaluation, acute management, and long-term abstinence planning 7

Post-Withdrawal Relapse Prevention

• After successful withdrawal management, relapse prevention treatment with acamprosate, disulfiram, or naltrexone should be offered, with selection based on patient preference, motivation, and availability 6
• Psychosocial support and encouragement to engage with mutual help groups like Alcoholics Anonymous are also recommended 6

Management of Alcohol Withdrawal

Pharmacological Management

• The American Association for the Study of Liver Diseases recommends continuing benzodiazepine therapy using symptom-triggered dosing guided by CIWA-Ar scores, as withdrawal symptoms can persist beyond 72 hours and require ongoing treatment until complete resolution 11
• Thiamine deficiency is present in 30-80% of alcohol-dependent patients, and thiamine 100-300 mg/day must be administered to all patients throughout the withdrawal period to prevent Wernicke encephalopathy 11
• Despite widespread belief, the superiority of short-acting benzodiazepines in liver disease is not validated by controlled trials, and all benzodiazepines are affected by hepatic insufficiency 11
• More than 70% of cirrhotic patients may not require pharmacological treatment, so dose only when symptoms are present 11
• Do not discontinue benzodiazepines prematurely based on day of admission alone—treat until symptom resolution 11
• Do not assume hepatic dysfunction absolutely contraindicates diazepam—symptom-triggered dosing is safe when monitored appropriately 11
• Infection (pneumonia, spontaneous bacterial peritonitis in cirrhotics) is a common complication that may complicate day 4 management 11
• Offer pharmacotherapy: acamprosate, naltrexone (if no severe liver disease), or disulfiram for relapse prevention 11
• Baclofen up to 80 mg/day is safe in liver disease, though dose escalation should be gradual in severe hepatic dysfunction 11